The QHNCC is currently participating in a multi-centre clinical trial, led by QBiotics Limited, of EBC-46 to treat cancer.
EBC-46 is a novel, natural, small molecule that is derived from the seeds of the Blushwood – an Australian native, tropical rainforest, shrub. EBC-46 has demonstrated rapid destruction of a variety of tumour types, with no apparent significant side effects, in a range of animals including standard mouse models and spontaneous tumours in dogs, cats and horses. QBiotics Limited is the process of developing EBC-46 as a human pharmaceutical. QHNCC is partnering with QBiotics Limited in a clinical trial to establish the safety of EBC-46 to treat human cancers.